Palvella Therapeutics, Inc. Repayment of Notes Receivable from Related Parties
Palvella Therapeutics, Inc. (PVLA) reported Repayment of Notes Receivable from Related Parties of $0 for the 3-month period ending 2014-03-31, per its 10-Q filed 2014-06-02.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RepaymentOfNotesReceivableFromRelatedParties · last filed 2014-06-02
- Palvella Therapeutics, Inc. repayment of notes receivable from related parties for the quarter ending 2014-03-31 was $0.00.
| Period end | Repayment of Notes Receivable from Related Parties 3 month | Repayment of Notes Receivable from Related Parties 9 month | Repayment of Notes Receivable from Related Parties 10 month |
|---|---|---|---|
| 2014-03-31 | $0.00 10-Q · filed 2014-06-02 | $0.00 10-Q · filed 2014-06-02 | $0.00 10-Q · filed 2014-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |